<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bodmer BS</submitter><funding>German Research Foundation</funding><funding>Ebola-Foresight.Deutsches Zentrum für Infektionsforschung </funding><funding>Chica and Heinz Schaller Foundation</funding><funding>German Center for Infection Research</funding><funding>Friedrich-Loeffler-Institut</funding><funding>German Ministry of Food and Agriculture</funding><pagination>2164216</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9858441</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>Ebolaviruses cause outbreaks of haemorrhagic fever in Central and West Africa. Some members of this genus such as Ebola virus (EBOV) are highly pathogenic, with case fatality rates of up to 90%, whereas others such as Reston virus (RESTV) are apathogenic for humans. Bombali virus (BOMV) is a novel ebolavirus for which complete genome sequences were recently found in free-tailed bats, although no infectious virus could be isolated. Its pathogenic potential for humans is unknown. To address this question, we first determined whether proteins encoded by the available BOMV sequence found in &lt;i>Chaerephon pumilus&lt;/i> were functional in &lt;i>in vitro&lt;/i> assays. The correction of an apparent sequencing error in the glycoprotein based on these data then allowed us to generate infectious BOMV using </pubmed_abstract><journal>Emerging microbes &amp; infections</journal><pubmed_title>&lt;i>In vivo&lt;/i> characterization of the novel ebolavirus Bombali virus suggests a low pathogenic potential for humans.</pubmed_title><pmcid>PMC9858441</pmcid><funding_grant_id>469065579</funding_grant_id><funding_grant_id>TTU 01.702</funding_grant_id><pubmed_authors>Heung M</pubmed_authors><pubmed_authors>Brunetti JE</pubmed_authors><pubmed_authors>Vallbracht M</pubmed_authors><pubmed_authors>Chlanda P</pubmed_authors><pubmed_authors>Wendt L</pubmed_authors><pubmed_authors>Romer S</pubmed_authors><pubmed_authors>Breithaupt A</pubmed_authors><pubmed_authors>Rodriguez E</pubmed_authors><pubmed_authors>Muller-Guhl J</pubmed_authors><pubmed_authors>Hoenen T</pubmed_authors><pubmed_authors>Bodmer BS</pubmed_authors><pubmed_authors>Winter SL</pubmed_authors><pubmed_authors>Henkel C</pubmed_authors><pubmed_authors>Muller A</pubmed_authors><pubmed_authors>Escudero-Perez B</pubmed_authors><pubmed_authors>Munoz-Fontela C</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>In vivo&lt;/i> characterization of the novel ebolavirus Bombali virus suggests a low pathogenic potential for humans.</name><description>Ebolaviruses cause outbreaks of haemorrhagic fever in Central and West Africa. Some members of this genus such as Ebola virus (EBOV) are highly pathogenic, with case fatality rates of up to 90%, whereas others such as Reston virus (RESTV) are apathogenic for humans. Bombali virus (BOMV) is a novel ebolavirus for which complete genome sequences were recently found in free-tailed bats, although no infectious virus could be isolated. Its pathogenic potential for humans is unknown. To address this question, we first determined whether proteins encoded by the available BOMV sequence found in &lt;i>Chaerephon pumilus&lt;/i> were functional in &lt;i>in vitro&lt;/i> assays. The correction of an apparent sequencing error in the glycoprotein based on these data then allowed us to generate infectious BOMV using </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Dec</publication><modification>2026-05-02T11:14:25.777Z</modification><creation>2024-11-20T12:10:15.622Z</creation></dates><accession>S-EPMC9858441</accession><cross_references><pubmed>36580440</pubmed><doi>10.1080/22221751.2022.2164216</doi></cross_references></HashMap>